Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Management of central nervous system lymphomas using monoclonal antibodies: challenges and opportunities Wong ETClin Cancer Res 2005[Oct]; 11 (19 Pt 2): 7151s-7157sMonoclonal antibodies (mAb) may change the management of central nervous system (CNS) lymphomas. This is due to the fact that traditional chemotherapies lack specificity for B-lymphoma cells and blood-brain barrier prevents adequate chemotherapy dosing in the CNS without significant systemic side effects. But in the past 5 years, the emergence of mAbs against specific receptors on B-lymphoma cells, either as a single agent or in combination with cytotoxic chemotherapies, may offer a better therapeutic index than conventional chemotherapies. The advantages of mAbs include high affinity to targets on lymphoma cells, their lack of pharmacodynamic or pharmacokinetic interactions with other drugs, and a potential for a synergistic therapeutic response when combined with conventional chemotherapies. Our review summarizes the biological behaviors of CNS lymphomas and the challenges and opportunities in using mAbs for CNS lymphomas.|Aged[MESH]|Antibodies, Monoclonal/chemistry/*therapeutic use[MESH]|Blood-Brain Barrier/metabolism[MESH]|Central Nervous System Neoplasms/*diagnosis/*therapy[MESH]|Gadolinium/pharmacology[MESH]|Glioma/pathology[MESH]|Humans[MESH]|Immunotherapy/*methods[MESH]|Lymphoma, B-Cell/immunology[MESH]|Lymphoma/*diagnosis/pathology/*therapy[MESH]|Middle Aged[MESH]|Radioimmunodetection/methods[MESH]|Radioimmunotherapy/methods[MESH]|Time Factors[MESH]|Treatment Outcome[MESH] |
